Consistently, the positive outcomes of the OLYMPIA trial suggest that PARPi will become a standard adjuvant treatment in patients treated with bulky or aggressive localized ER+/HER2- cancers, at high risk of relapse leading to a recent update of ASCO guidelines [76]. This evidence concerns the gene ERBB2 and cancer.